Specifically, DCBLD2, a biomarker with largest risk to develop chemoresistance, was reported to promote CRC progression, and mediate drug resistance to 5-FU, a first-line drug for CRC (He et al., 2020; Xie et al., 2021). The gene discussed is DCBLD2; the disease is colorectal carcinoma.